1
|
Sezer O, Nursal AF, Gunal O, Gorgun S, Tekcan A, Unluguzel Ustun G, Yigit S. Evaluating interleukin-6 levels and the rs1800795 variant in Turkish patients with COVID-19: a prospective cohort study. Nucleosides Nucleotides Nucleic Acids 2023; 43:377-390. [PMID: 37787093 DOI: 10.1080/15257770.2023.2263490] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/09/2022] [Accepted: 09/21/2023] [Indexed: 10/04/2023]
Abstract
BACKGROUND Coronavirus disease 2019 (COVID-19) is a multisystem disease of global significance. Interleukin (IL)-6 is a soluble cytokine with a pleiotropic effect on inflammation and the immune response. OBJECTIVES Investigate the relationship between the interleukin 6 (IL6) rs1800795 variant and IL6 level in Turkish patients with COVID-19 disease. DESIGN Prospective cohort study. SETTING Tertiary care hospital. PATIENTS AND METHODS Real-time polymerase chain reaction (RT-PCR)-positive and/or chest computerized tomography (CT) scan-compatible COVID-19 patients were enrolled in the study. The clinical data and whole blood samples were collected from April 1, 2020, to August 1, 2020. IL6 rs1800795 genotyping was performed by the PCR-restriction fragment-length polymorphism (RFLP) method in 148 patients. Serum IL-6 concentrations were measured using the ELISA method in 89 patients. We evaluated the patients in three groups: asymptomatic, symptomatic, and intensive care unit patients. MAIN OUTCOME MEASURES IL6 rs1800795 genotype frequencies and serum IL-6 levels in COVID-19 patients with different clinical presentations. SAMPLE SIZE 148 cases. RESULTS IL6 rs1800795 GG genotype and G allele frequency increased in PCR positive patients compared to PCR-negative patients (p ˂ 0.000). IL6 rs1800795 GC genotype and C allele frequency were lower in PCR-positive patients than in PCR-negative patients. IL6 rs1800795 GG genotype and G allele frequency were higher in asymptomatic patients than in the symptomatic and intensive care unit groups. The IL6 rs1800795 C allele frequency was lower in asymptomatic patients than in the symptomatic and intensive care unit groups. IL6 rs1800795 GG genotype and G allele frequency were higher in CT negative patients than CT positive patients, while IL6 GC genotype and C allele frequency were higher in CT positive patients than negative patients. IL6 level elevation was seen in the asymptomatic patients compared to the symptomatic and intensive care unit groups. CONCLUSIONS These findings suggest that IL6 rs1800795 may contribute to the susceptibility of COVID-19 in people to Turkish origin. LIMITATIONS Further large-scale studies in different genetic populations are needed as this is a single-center, prospective study.
Collapse
Affiliation(s)
- Ozlem Sezer
- Department of Medical Genetics, Faculty of Medicine, Samsun University, Samsun, Turkey
| | - Ayse Feyda Nursal
- Department of Medical Genetics, Faculty of Medicine, Hitit University, Corum, Turkey
| | - Ozgur Gunal
- Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Samsun University, Samsun, Turkey
| | - Selim Gorgun
- Department of Microbiology and Clinical Microbiology, Samsun Training and Research Hospital, University of Health Sciences, Samsun, Turkey
| | - Akin Tekcan
- Department of Medical Biology, Faculty of Medicine, Amasya University, Amasya, Turkey
| | - Goksenin Unluguzel Ustun
- Department of Medical Biochemistry, Samsun Education and Research Hospital, University of Health Sciences, Samsun, Turkey
| | - Serbulent Yigit
- Department of Genetics, Faculty of Veterinary Medicine, Ondokuz Mayis University, Samsun, Turkey
| |
Collapse
|
2
|
Sezer O, Gunal O, Aci R, Keskin A. Possible effect of genetic background in thrombophilia genes on clinical severity of patients with coronavirus disease-2019: A prospective cohort study. Baghdad J Biochem Appl Biol Sci 2022. [DOI: 10.47419/bjbabs.v3i03.141] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Background and objective: Thrombotic and microangiopathic effects have been reported in Coronavirus Disease-2019 (COVID-19) patients. In the present study, we aimed to examine the relationship between hereditary thrombophilia factors and the clinical picture severity of COVID-19 patients.
Methods: Ninety COVID-19 patients were included and grouped according to the severity to three groups: severe/critical (n=30), mild/moderate (n=30) and asymptomatic (n=30). Hereditary thrombophilia genetic markers [prothrombin (FII) G20210A, factor V Leiden (FVL) G1691A, factor XIII (FXIII) V34L, methylene tetrahydrofolate reductase (MTHFR) A1298C and C677T, and plasminogen activator inhibitor-1 (PAI-1) 4G & 5G] were genotyped for all patients.
Results: Seventeen (18.9%) patients had the polymorphism 4G/4G PAI-1 and 48 (53.3%) had 4G/5G. In addition, the heterozygous GA FVL, MTHRF677CT, and MTHRF1298AC polymorphisms were detected in 11 (12.2%), 26 (28.9%), and 38 (42.2%) patients, respectively. The rate of severe/critical patients with PAI 4G/5G gene polymorphism was higher than the asymptomatic+moderate/mild patients, and the rate of severe/critically ill patients with PAI 4G/4G polymorphism was found to be lower than the asymptomatic+moderate/mild patients. No difference was evidenced between the distribution of deceased and survivors of the genotype groups.
Conclusions: In the present study, we found that heterozygous 4G/5G PAI-1 polymorphism is associated with critical or severe COVID-19 picture, and that FVL, MTHFR, FXIII, and prothrombin polymorphisms were not directly related to COVID-19 severity.
Collapse
|
3
|
Uzun O, Akpolat T, Varol A, Turan S, Bektas SG, Cetinkaya PD, Dursun M, Bakan N, Ketencioglu BB, Bayrak M, Baris SA, Guner R, Gunal O, Nural S, Deniz PP, Toprak OB, Ozkan G, Gumus A, Kerget F, Ercelik M, Ataoglu O, Yuksel A, Ates G, Kutsoylu OE, Kose N, Kizilirmak D, Keskin S, Gultekin O, Coskun N, Yilmaz ES, Uslu S, Basyigit İ, Ergan B, Deveci F, Yakar MN, Zuhur C, Sagcan G, Yuce ZT, Kuluozturk M, Sezgin ME, Sezgin ENA, Havlucu Y, Cuhadaroglu C, Kilinc O, Boyaci H, Altunay H, Akti M, Dursun ZB, Kalem AK, Isik SA, Akyildiz L, Aykac N, Almaz MS, Kokturk N, Itil O. COVID-19: vaccination vs. hospitalization. Infection 2022; 50:747-752. [PMID: 34984646 PMCID: PMC8725959 DOI: 10.1007/s15010-021-01751-1] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2021] [Accepted: 12/21/2021] [Indexed: 12/20/2022]
Abstract
Objective Vaccination is the most efficient way to control the coronavirus disease 2019 (COVID-19) pandemic, but vaccination rates remain below the target level in most countries. This multicenter study aimed to evaluate the vaccination status of hospitalized patients and compare two different booster vaccine protocols. Setting Inoculation in Turkey began in mid-January 2021. Sinovac was the only available vaccine until April 2021, when BioNTech was added. At the beginning of July 2021, the government offered a third booster dose to healthcare workers and people aged > 50 years who had received the two doses of Sinovac. Of the participants who received a booster, most chose BioNTech as the third dose. Methods We collected data from 25 hospitals in 16 cities. Patients hospitalized between August 1 and 10, 2021, were included and categorized into eight groups according to their vaccination status. Results We identified 1401 patients, of which 529 (37.7%) were admitted to intensive care units. Nearly half (47.8%) of the patients were not vaccinated, and those with two doses of Sinovac formed the second largest group (32.9%). Hospitalizations were lower in the group which received 2 doses of Sinovac and a booster dose of BioNTech than in the group which received 3 doses of Sinovac. Conclusion Effective vaccinations decreased COVID-19-related hospitalizations. The efficacy after two doses of Sinovac may decrease over time; however, it may be enhanced by adding a booster dose. Moreover, unvaccinated patients may be persuaded to undergo vaccination.
Collapse
Affiliation(s)
- Oguz Uzun
- Department of Pulmonary Medicine, Faculty of Medicine, Ondokuz Mayis University, Samsun, Turkey.
- Ondokuz Mayıs Üniversitesi Göğüs Hst, 55139, Samsun, Turkey.
| | - Tekin Akpolat
- Department of Internal Medicine and Nephrology, Faculty of Medicine, Istinye University, Istanbul, Turkey
| | | | - Sema Turan
- Department of Intensive Care Unit, Ankara City Hospital, Ankara, Turkey
| | | | | | | | - Nurten Bakan
- Şehit Prof Dr İlhan Varank Training and Research Hospital, İstanbul, Turkey
| | | | | | - Serap Argun Baris
- Department of Pulmonary Disease, School of Medicine, Kocaeli University, Kocaeli, Turkey
| | - Rahmet Guner
- Department of Infectious Diseases and Clinical Microbiology, Ankara City Hospital, Yildirim Beyazit University, Ankara, Turkey
| | - Ozgur Gunal
- Department of Infectious Diseases and Clinical Microbiology, Samsun Training and Research Hospital, University of Medical Science, Samsun, Turkey
| | - Serkan Nural
- Department of Pulmonary Medicine, Training and Research Hospital, Hatay, İstanbul, Turkey
| | | | - Oya Baydar Toprak
- Department of Pulmonary Medicine, Faculty of Medicine, Cukuroca University, Adana, Turkey
| | - Gulcihan Ozkan
- Maslak Acibadem Hospital, Operating Room Services Department and Private Acıbadem Maslak Hospital, Vocational School, Nişantaşı University, İstanbul, Turkey
| | | | - Ferhan Kerget
- Department of Infection Diseases and Clinical Microbiology, Faculty of Medicine, Erzurum Regional Education and Research Hospital, Health Sciences University, Erzurum, Turkey
| | | | | | - Aycan Yuksel
- Department of Pulmonary Medicine, Faculty of Medicine, Ufuk University, Ankara, Turkey
| | - Gungor Ates
- Genesis Private Hospital, Diyarbakır, Turkey
| | - Oya Eren Kutsoylu
- Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey
| | | | - Deniz Kizilirmak
- Department of Pulmonary Medicine, Faculty of Medicine, Celal Bayar University, Manisa, Turkey
| | | | | | - Nilüfer Coskun
- Şehit Prof Dr İlhan Varank Training and Research Hospital, İstanbul, Turkey
| | - Emine Serap Yilmaz
- Department of Pulmonary Medicine, Medical Faculty, Training and Research Hospital, Ordu University, Ordu, Turkey
| | - Selen Uslu
- Department of Pulmonary Medicine, Medical Faculty, Training and Research Hospital, Ordu University, Ordu, Turkey
| | - İlknur Basyigit
- Department of Pulmonary Disease, School of Medicine, Kocaeli University, Kocaeli, Turkey
| | - Begüm Ergan
- Division of Intensive Care, Department of Pulmonary and Critical Care, Faculty of Medicine, Dokuz Eylül University, Izmir, Turkey
| | - Figen Deveci
- Department of Pulmonary Medicine, Faculty of Medicine, Firat University, Elazıg, Turkey
| | - Mehmet Nuri Yakar
- Division of Intensive Care, Department of Anaesthesiology and Reanimation, Faculty of Medicine, Dokuz Eylül University, Izmir, Turkey
| | | | | | - Zeynep Ture Yuce
- Department of Infectious Diseases and Clinical Microbiology, Erciyes University, Kayseri, Turkey
| | - Mutlu Kuluozturk
- Department of Pulmonary Medicine, Faculty of Medicine, Firat University, Elazıg, Turkey
| | | | | | - Yavuz Havlucu
- Department of Pulmonary Medicine, Faculty of Medicine, Celal Bayar University, Manisa, Turkey
| | | | - Oguz Kilinc
- Department of Pulmonary Medicine, Faculty of Medicine, Dokuz Eylül University, İzmir, Turkey
| | - Hasim Boyaci
- Department of Pulmonary Disease, School of Medicine, Kocaeli University, Kocaeli, Turkey
| | | | - Mehmet Akti
- Siirt Training and Research Hospital, Siirt, Turkey
| | - Zehra Bastepe Dursun
- Department of Infectious Diseases and Clinical Microbiology, Kayseri City Hospital, Health Science University, Kayseri, Turkey
| | - Ayse Kaya Kalem
- Department of Infectious Diseases and Clinical Microbiology, Ankara City Hospital, Yildirim Beyazit University, Ankara, Turkey
| | - Sinem Akkaya Isik
- Sultan Abdülhamid Han Training and Research Hospital, İstanbul, Turkey
| | | | | | | | - Nurdan Kokturk
- Department of Pulmonary Medicine, Faculty of Medicine, Gazi University, Ankara, Turkey
| | - Oya Itil
- Department of Pulmonary Medicine, Faculty of Medicine, Dokuz Eylul University, İzmir, Turkey
| |
Collapse
|
4
|
Erdinc FS, Dokuzoguz B, Unal S, Komur S, Inkaya AC, Inan D, Karaoglan I, Deveci A, Celen MK, Kose S, Erben N, Senturk GC, Heper Y, Kutlu SS, Hatipoglu CA, Sumer S, Kandemir B, Sirmatel F, Bayindir Y, Yilmaz E, Ersoy Y, Kazak E, Yildirmak MT, Kayaaslan B, Ozden K, Sener A, Kara A, Gunal O, Birengel S, Akbulut A, Yetkin F, Cuvalci NO, Sargin F, Pullukcu H, Gokengin D, Multicentric Hiv Study Group. Temporal Trends in the Epidemiology of HIV in Turkey. Curr HIV Res 2021; 18:258-266. [PMID: 32342820 DOI: 10.2174/1570162x18666200427223823] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2019] [Revised: 04/03/2020] [Accepted: 04/14/2020] [Indexed: 01/07/2023]
Abstract
OBJECTIVE The aim of this study was to analyze the temporal trends of HIV epidemiology in Turkey from 2011 to 2016. METHODS Thirty-four teams from 28 centers at 17 different cities participated in this retrospective study. Participating centers were asked to complete a structured form containing questions about epidemiologic, demographic and clinical characteristics of patients presented with new HIV diagnosis between 2011 and 2016. Demographic data from all centers (complete or partial) were included in the analyses. For the cascade of care analysis, 15 centers that provided full data from 2011 to 2016 were included. Overall and annual distributions of the data were calculated as percentages and the Chi square test was used to determine temporal changes. RESULTS A total of 2,953 patients between 2011 and 2016 were included. Overall male to female ratio was 5:1 with a significant increase in the number of male cases from 2011 to 2016 (p<0.001). The highest prevalence was among those aged 25-34 years followed by the 35-44 age bracket. The most common reason for HIV testing was illness (35%). While the frequency of sex among men who have sex with men increased from 16% to 30.6% (p<0.001) over the study period, heterosexual intercourse (53%) was found to be the most common transmission route. Overall, 29% of the cases presented with a CD4 count of >500 cells/mm3 while 46.7% presented with a CD4 T cell count of <350 cells/mm3. Among newly diagnosed cases, 79% were retained in care, and all such cases initiated ART with 73% achieving viral suppression after six months of antiretroviral therapy. CONCLUSION The epidemiologic profile of HIV infected individuals is changing rapidly in Turkey with an increasing trend in the number of newly diagnosed people disclosing themselves as MSM. New diagnoses were mostly at a young age. The late diagnosis was found to be a challenging issue. Despite the unavailability of data for the first 90, Turkey is close to the last two steps of 90-90-90 targets.
Collapse
Affiliation(s)
- F S Erdinc
- Ankara Training and Research Hospital, Infectious Diseases and Clinical Microbiology, Ankara, Turkey
| | - B Dokuzoguz
- Ankara Numune Training and Researh Hospital, Infectious Diseases and Clinical Microbiology, Ankara, Turkey
| | - S Unal
- Hacettepe Universitesi Hastaneleri, Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkey
| | - S Komur
- Cukurova University, Department of Infectious Diseases and Clinical Microbiology, Adana, Turkey
| | - A C Inkaya
- Ankara Numune Training and Researh Hospital, Infectious Diseases and Clinical Microbiology, Ankara, Turkey
| | - D Inan
- Akdeniz University, Department of Infectious Diseases and Clinical Microbiology, Antalya, Turkey
| | - I Karaoglan
- Gaziantep University, Department of Infectious Diseases and Clinical Microbiology, Gaziantep, Turkey
| | - A Deveci
- Ondokuz Mayis University, Department of Infectious Diseases and Clinical Microbiology, Samsun, Turkey
| | - M K Celen
- Dicle University, Department of Infectious Diseases and Clinical Microbiology, Diyarbakır, Turkey
| | - S Kose
- Izmir Tepecik Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, İzmir, Turkey
| | - N Erben
- Eskisehir Osmangazi University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Eskisehir, Turkey
| | - G C Senturk
- Diskapi Yildirim Beyazit Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkey
| | - Y Heper
- Uludag University, Department of Infectious Diseases and Clinical Microbiology, Bursa, Turkey
| | - S S Kutlu
- Pamukkale University, Department of Infectious Diseases and Clinical Microbiology, Denizli, Turkey
| | - C A Hatipoglu
- Ankara Training and Research Hospital, Infectious Diseases and Clinical Microbiology, Ankara, Turkey
| | - S Sumer
- Selcuk University, Department of Infectious Diseases and Clinical Microbiology, Konya, Turkey
| | - B Kandemir
- Necmettin Erbakan University, Meram Medical Faculty Hospital, Department of Infectious Diseases and Clinical Microbiology, Konya, Turkey
| | - F Sirmatel
- Abant Izzet Baysal University, Department of Infectious Diseases and Clinical Microbiology, Bolu, Turkey
| | - Y Bayindir
- Inonu University, Department of Infectious Diseases and Clinical Microbiology, Malatya, Turkey
| | - E Yilmaz
- Uludag University, Department of Infectious Diseases and Clinical Microbiology, Bursa, Turkey
| | - Y Ersoy
- Inonu University, Department of Infectious Diseases and Clinical Microbiology, Malatya, Turkey
| | - E Kazak
- Uludag University, Department of Infectious Diseases and Clinical Microbiology, Bursa, Turkey
| | - M T Yildirmak
- Okmeydani Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey
| | - B Kayaaslan
- Yildirim Beyazit University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkey
| | - K Ozden
- Ataturk University, Department of Infectious Diseases and Clinical Microbiology, Erzurum, Turkey
| | - A Sener
- Canakkale Onsekiz Mart University, Department of Infectious Diseases and Clinical Microbiology, Canakkale, Turkey
| | - A Kara
- Hacettepe University Ihsan Dogramaci Children's Hospital, Department of Infectious Diseases, Ankara, Turkey
| | - O Gunal
- Samsun Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Samsun, Turkey
| | - S Birengel
- Ankara University Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Ankara, Turkey
| | - A Akbulut
- Firat University, Department of Infectious Diseases and Clinical Microbiology, Elazig, Turkey
| | - F Yetkin
- Inonu University, Department of Infectious Diseases and Clinical Microbiology, Malatya, Turkey
| | - N O Cuvalci
- Antalya Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Antalya, Turkey
| | - F Sargin
- Medeniyet University Goztepe Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Istanbul, Turkey
| | - H Pullukcu
- Ege University, Department of Infectious Diseases and Clinical Microbiology, Izmir, Turkey
| | - D Gokengin
- Ege University, Department of Infectious Diseases and Clinical Microbiology, Izmir, Turkey
| | | |
Collapse
|
5
|
Gunal O, Sezer O, Ustun GU, Ozturk CE, Sen A, Yigit S, Demirag MD. Angiotensin-converting enzyme-1 gene insertion/deletion polymorphism may be associated with COVID-19 clinical severity: a prospective cohort study. Ann Saudi Med 2021; 41:141-146. [PMID: 34085542 PMCID: PMC8176375 DOI: 10.5144/0256-4947.2021.141] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND Angiotensin-converting enzyme (ACE) insertion/deletion (I/D) polymorphism may play a role in the pathogenesis of coronavirus-19 disease (COVID-19). OBJECTIVES Investigate the relationship between ACE I/D polymorphism and the clinical severity of COVID-19. DESIGN Prospective cohort study. SETTING Tertiary care hospital. PATIENTS AND METHODS The study included COVID-19 patients with asymptomatic, mild, and severe disease with clinical data and whole blood samples collected from 1 April 2020 to 1 July 2020. ACE I/D genotypes were determined by polymerase chain reaction and agarose gel electrophoresis. MAIN OUTCOME MEASURE ACE DD, DI and II genotypes frequencies. SAMPLE SIZE 90 cases, 30 in each disease severity group. RESULTS Age and the frequency of general comorbidity increased significantly from the asymptomatic disease group to the severe disease group. Advanced age, diabetes mellitus and presence of ischemic heart disease were independent risk factors for severe COVID-19 [OR and 95 % CI: 1.052 (1.021-1.083), 5.204 (1.006-26.892) and 5.922 (1.109-31.633), respectively]. The ACE II genotype was the dominant genotype (50%) in asymptomatic patients, while the DD genotype was the dominant genotype (63.3 %) in severe disease. The ACE II geno-type was protective against severe COVID-19 [OR and 95% CI: .323 (.112-.929)]. All nine patients (8.9%) who died had severe disease. CONCLUSIONS The clinical severity of COVID-19 infection may be associated with the ACE I/D polymorphism. LIMITATIONS Small sample size and single center. CONFLICT OF INTEREST None.
Collapse
Affiliation(s)
- Ozgur Gunal
- From the Department of Infectious Diseases and Clinical Microbiology, Samsun Education and Research Hospital, Samsun, Turkey
| | - Ozlem Sezer
- From the Medical Genetics, Samsun Education and Research Hospital, Samsun, Turkey
| | | | - Cagatay Erman Ozturk
- From the Anaesthesiology and Reanimation, Samsun Education and Research Hospital, Samsun, Turkey
| | - Ahmet Sen
- From the Anaesthesiology and Reanimation, Samsun Education and Research Hospital, Samsun, Turkey
| | - Serbulent Yigit
- From the Department of Genetics, Faculty of Veterinary Medicine, Ondokuz Mayis University, Samsun, Turkey
| | - Mehmet Derya Demirag
- From the Department of Internal Medicine, Section of Rheumatology, Samsun Education and Research Hospital, Samsun, Turkey
| |
Collapse
|
6
|
Aydın M, Azak E, Bilgin H, Menekse S, Asan A, Mert HTE, Yulugkural Z, Altunal LN, Hatipoğlu ÇA, Tuncer Ertem G, Altunok ES, Demirkaya MH, Çeviker SA, Akgul F, Memis Z, Konya P, Azap A, Aydin G, Korkmaz D, Karakoç ZÇ, Yapar D, Karakecili F, Gunal O, Keske S, Kapmaz M, Kader C, Demirel A, Ergönül Ö. Changes in antimicrobial resistance and outcomes of health care-associated infections. Eur J Clin Microbiol Infect Dis 2021; 40:1737-1742. [PMID: 33586014 DOI: 10.1007/s10096-020-04140-y] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/25/2020] [Accepted: 12/20/2020] [Indexed: 11/26/2022]
Abstract
To describe the change in the epidemiology of health care-associated infections (HAI), resistance and predictors of fatality we conducted a nationwide study in 24 hospitals between 2015 and 2018. The 30-day fatality rate was 22% in 2015 and increased to 25% in 2018. In BSI, a significant increasing trend was observed for Candida and Enterococcus. The highest rate of 30-day fatality was detected among the patients with pneumonia (32%). In pneumonia, Pseudomonas infections increased in 2018. Colistin resistance increased and significantly associated with 30-day fatality in Pseudomonas infections. Among S. aureus methicillin, resistance increased from 31 to 41%.
Collapse
Affiliation(s)
- Mehtap Aydın
- Department of Infectious Diseases and Clinical Microbiology, Umraniye Research and Training Hospital University of Health Science, Elmalıkent, Adem Yavuz Cd., 34764, Ümraniye/İstanbul, Turkey.
| | - Emel Azak
- Department of Infectious Diseases and Clinical Microbiology, School of Medicine, University of Kocaeli, Kocaeli, Turkey
| | - Hüseyin Bilgin
- School of Medicine, Department of Infectious Diseases and Clinical Microbiology, Marmara University, Istanbul, Turkey
| | - Sirin Menekse
- Department of Infectious Diseases and Clinical Microbiology, Kartal Koşuyolu Research and Training Hospital, Istanbul, Turkey
| | - Ali Asan
- Department of Infectious Diseases and Clinical Microbiology, University of Health Science, Bursa, Turkey
| | - Habibe Tülin Elmaslar Mert
- School of Medicine, Department of Infectious Diseases and Clinical Microbiology, Trakya University, Edirne, Turkey
| | - Zerrin Yulugkural
- School of Medicine, Department of Infectious Diseases and Clinical Microbiology, Trakya University, Edirne, Turkey
| | - Lutfiye Nilsun Altunal
- Department of Infectious Diseases and Clinical Microbiology, Umraniye Research and Training Hospital University of Health Science, Elmalıkent, Adem Yavuz Cd., 34764, Ümraniye/İstanbul, Turkey
| | - Çiğdem Ataman Hatipoğlu
- Department of Infectious Diseases and Clinical Microbiology, University of Health Science Ankara Research and Training Hospital, Ankara, Turkey
| | - Gunay Tuncer Ertem
- Department of Infectious Diseases and Clinical Microbiology, University of Health Science Ankara Research and Training Hospital, Ankara, Turkey
| | - Elif Sargın Altunok
- Department of Infectious Diseases and Clinical Microbiology, Gaziosmanpaşa Research and Training Hospital, Istanbul, Turkey
| | - Melike Hamiyet Demirkaya
- Department of Infectious Diseases and Clinical Microbiology, Baskent University School of Medicine, Ankara, Turkey
| | - Sevil Alkan Çeviker
- University of Health Science Kütahya Evliya Çelebi Research and Training Hospital, Kütahya, Turkey
| | - Fethiye Akgul
- Department of Infectious Diseases and Clinical Microbiology, Batman State Hospital, Batman, Turkey
| | - Zeynep Memis
- School of Medicine, Department of Infectious Diseases and Clinical Microbiology, Istanbul University, Istanbul, Turkey
| | - Petek Konya
- Department of Infectious Diseases and Clinical Microbiology, Afyonkarahisar University of Health Science, Afyon, Turkey
| | - Alpay Azap
- School of Medicine, Department of Infectious Diseases and Clinical Microbiology, Ankara University, Ankara, Turkey
| | - Gule Aydin
- School of Medicine, Department of Infectious Diseases and Clinical Microbiology, Ankara University, Ankara, Turkey
| | - Derya Korkmaz
- Department of Infectious Diseases and Clinical Microbiology, Afyonkarahisar State Hospital, Afyon, Turkey
| | - Zehra Çagla Karakoç
- Department of Infectious Diseases and Clinical Microbiology, Istinye University, Istanbul, Turkey
| | - Derya Yapar
- Department of Infectious Diseases and Clinical Microbiology School of Medicine, Hitit University, Corum, Turkey
| | - Faruk Karakecili
- School of Medicine, Department of Infectious Diseases and Clinical Microbiology, Erzincan Binali Yıldırım University, Erzincan, Turkey
| | - Ozgur Gunal
- University of Health Science Samsun Research and Training Hospital, Samsun, Turkey
| | - Siran Keske
- School of Medicine Department of Infectious Diseases and Clinical Microbiology, Koc University, Istanbul, Turkey
| | - Mahir Kapmaz
- School of Medicine Department of Infectious Diseases and Clinical Microbiology, Koc University, Istanbul, Turkey
| | - Cigdem Kader
- School of Medicine, Department of Infectious Diseases and Clinical Microbiology, Bozok University, Yozgat, Turkey
| | - Aslıhan Demirel
- Department of Infectious Diseases and Clinical Microbiology, Florans Nightingale Hospital, Istanbul, Turkey
| | - Önder Ergönül
- School of Medicine Department of Infectious Diseases and Clinical Microbiology, Koc University, Istanbul, Turkey
| |
Collapse
|
7
|
|
8
|
Taskin MH, Gunal O, Arslan S, Kaya B, Kilic SS, Akkoyunlu GK, Yazici Z. Epidemiological findings on Hepatitis C infection in a tertiary level hospital in mid-northern Anatolia in Turkey: A four-year analysis. Trop Biomed 2020; 37:227-236. [PMID: 33612734] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
The hepatitis C virus (HCV) is a blood-borne pathogen that causes acute or chronic infection of the liver, sometimes leading to serious liver damage and fatality. The objective of this study was to evaluate HCV prevalence in patients attending the Regional Training and Research Hospital for Medical Examination and Surgery in Samsun Province of Turkey between 2014 and 2017. Blood specimens taken from 152 596 patients were screened for HCV infection by using the anti-HCV assay. Seropositive samples were subjected to polymerase chain reaction (PCR) testing in order to determine whether the HCV infection was active. Genotyping was then performed. Overall, HCV seropositivity and active HCV infection were 2.76% and 2.05%, respectively. Foreign nationals accounted for 5.61% of the seropositive samples and 1.37% of active HCV infective samples. We further report that 2017 was the year with the highest seroprevalence which was 3.64%. HCV genotype 1 was the most common genotype detected in residents of Samsun Province at 89.86%, followed by Genotype 3 at 4.54%. This study provides important information on the levels of HCV infection in the Samsun region of Turkey. The data indicate that there was a rising trend of HCV infection between 2014 and 2017.
Collapse
Affiliation(s)
- M H Taskin
- Department of Medical Microbiology, Samsun Training and Research Hospital, University of Health Sciences, Samsun, Turkey
| | - O Gunal
- Department of Infectious Disease Samsun Training and Research Hospital, University of Health Sciences, Samsun, Turkey
| | - S Arslan
- Department of Biometry, Faculty of Veterinary Medicine, Ondokuz Mayis University, Samsun, Turkey
| | - B Kaya
- Department of Emergency Medicine, Ankara Numune Training and Research Hospital, University of Health Sciences, Ankara, Turkey
| | - S S Kilic
- 5Department of Infectious Disease Samsun Training and Research Hospital, University of Health Sciences, Samsun, Turkey
| | - G K Akkoyunlu
- Department of Haematology Samsun Training and Research Hospital, University of Health Sciences, Samsun, Turkey
| | - Z Yazici
- Department of Virology, Faculty of Veterinary Medicine, Ondokuz Mayis University, Samsun, Turkey
| |
Collapse
|
9
|
Duygu F, Sari T, Gunal O, Barut S, Atay A, Aytekin F. Cutaneous Findings of Crimean-Congo Hemorrhagic Fever: a Study of 269 Cases. Jpn J Infect Dis 2018; 71:408-412. [PMID: 29962486 DOI: 10.7883/yoken.jjid.2018.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Crimean-Congo hemorrhagic fever (CCHF) is a zoonotic viral disease. We aimed to investigate the cutaneous manifestations of CCHF and reveal their associations with fatality. Two hundred and sixty-nine patients diagnosed with CCHF were assessed. Skin findings were observed in 170 (63.2%) patients. A facial rash was the most common cutaneous finding (n = 82, 30.5%). In severe cases, hemorrhagic cutaneous manifestations (petechiae and ecchymoses) were recognized. A statistically significant correlation was obtained between cutaneous manifestations and fatality, and it was determined that there was a strong positive correlation between fatality and ecchymosis (r = 567, p < 0.001). In addition, a logistic regression analysis was performed, and death occurred 4.69 times more in those with skin signs than in those without. We hypothesize that CCHF patients with ecchymosis are at the highest risk and that cutaneous findings can contribute to the prognosis of CCHF.
Collapse
Affiliation(s)
- Fazilet Duygu
- Department of Infectious Diseases and Clinical Microbiology, Ankara Oncology Training and Research Hospital
| | - Tugba Sari
- Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Pamukkale University
| | - Ozgur Gunal
- Department of Infectious Diseases and Clinical Microbiology, Samsun Training and Research Hospital
| | - Sener Barut
- Department of Infectious Diseases and Clinical Microbiology, Faculty of Medicine, Gaziosmanpasa University
| | - Ayfer Atay
- Department of Infectious Diseases and Clinical Microbiology, Bakirköy Dr. Sadi Konuk Training and Research Hospital
| | - Feyza Aytekin
- Department of Infectious Diseases and Clinical Microbiology, Ministry of Health-Giresun University Dr. A. Ilhan Ozdemir Training and Research Hospital
| |
Collapse
|
10
|
Gunal O, Yigit S, Yalcın AD, Celik B, Barut S, Demir O, Ates O, Duygu F, Kaya S, Rustemoglu A, Sezer O. The IL4-VNTR P1 Allele, IL4-VNTR P2P2 Genotype, and IL4-VNTR_IL6-174CG P2P1-GG Genotype Are Associated with an Increased Risk of Brucellosis. Jpn J Infect Dis 2017; 70:61-64. [PMID: 27169944 DOI: 10.7883/yoken.jjid.2015.550] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
In this study, associations between IL-4, IL-6, and macrophage migration inhibitory factor (MIF) polymorphisms and susceptibility to brucellosis were investigated. Consecutive adult patients with no known treatment against brucellosis and who did not have any other autoimmune and/or chronic disorders, were included in this study (n = 120, Group I). Age and sex-matched controls who had no other autoimmune and/or chronic disorders were also included (n = 120, healthy volunteers, Group II). The IL4_P2P2 genotype, IL4_P1 allele, and IL4_variable number of tandem repeats (VNTR)_IL6-174CG compound genotype were found to be more frequent in the patient group than in control subjects. There were significant differences between the patients and controls with respect to the frequencies of the IL4_P2P2 genotype (77.5% versus 87.5%; p = 0.001; OR, 0.36; 95% confidence interval [CI], 0.21-0.62) and the IL4_P1 allele (12.1% versus 6.7%; p = 0.030; OR, 0.92; CI, 1.02-3.64). The IL4-VNTR_IL6-174CG compound genotype was also present at a significantly higher frequency in the patient group than in control subjects (11.7% versus 4.2%; p = 0.027, OR, 3.04; CI, 1.06-8.68). No statistically significant differences in the frequencies of the IL-6-174, MIF-173, IL-4_P1P1, and IL4_P2P1 genotypes were observed between patients and control subjects. The IL4_VNTR P1 allele, P2P2 genotypes, and IL4-VNTR_IL6-174CG P2P1-GG genotypes are common in southern Turkey, and carriers of these polymorphisms are susceptible to brucellosis.
Collapse
Affiliation(s)
- Ozgur Gunal
- Department of Infectious Diseases and Clinical Microbiology, Samsun Training and Research Hospital
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Harman R, Yildirim E, Gunal O, Yalcin AD, Namiduru M, Sokucu M, Eyigun CP. Acute Generalized Exanthematous Pustulosis Due to Pyrazinamide in a Patient Receiving Antituberculous Treatment: A Case Report. Klimik Dergisi 2016. [DOI: 10.5152/kd.2016.32] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
12
|
Erdem H, Ak O, Elaldi N, Demirdal T, Hargreaves S, Nemli SA, Cag Y, Ulug M, Naz H, Gunal O, Sirmatel F, Sipahi OR, Alpat SN, Ertem-Tuncer G, Sozen H, Evlice O, Meric-Koc M, Dogru A, Koksaldi-Motor V, Tekin R, Ozdemir D, Ozturk-Engin D, Savasci U, Karagoz E, Cekli Y, Inan A. Infections in travellers returning to Turkey from the Arabian peninsula: a retrospective cross-sectional multicenter study. Eur J Clin Microbiol Infect Dis 2016; 35:903-10. [PMID: 26964538 PMCID: PMC7087946 DOI: 10.1007/s10096-016-2614-z] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2016] [Accepted: 02/17/2016] [Indexed: 11/17/2022]
Abstract
Mass gatherings pooling people from different parts of the world—the largest of which is to Mecca, Saudi Arabia, for Hajj—may impose risks for acquisition and dissemination of infectious diseases. A substantial number of pilgrims to Hajj and Umrah are Turkish citizens (456,000 in 2014) but data are lacking on scale of the problem. We did a retrospective cross-sectional multicenter study in Turkey to explore the range of infections among inpatients who had recently returned from the Arabian Peninsula. Our inclusion criteria were patients who had acquired an infection during their trip to an Arabian Peninsula country, or who became symptomatic within 1 week of their return. The data were collected retrospectively for January 1, 2013 and March 1, 2015. 185 Turkish patients were recruited to the study across 15 referral centers with travel associated infectious diseases after returning from Arabian Peninsula countries (predominantly Saudi Arabia 163 [88.1 %] for religious purposes 162 [87.5 %]). Seventy four (40.0 %) of them were ≥ 65 years old with numerous comorbidities including diabetes (24.3 %) and COPD (14.1 %). The most common clinical diagnosis was respiratory tract infections (169 [91.5 %]), followed by diarrheal diseases (13 [7 %]), and there was one case of MERS-CoV. Patients spent a median of 5 (3–7) days as hospital inpatients and overall mortality was 1.1 %. Returning travellers from the Arabian Peninsula present as inpatients with a broad range of infectious diseases similar to common community acquired infections frequently seen in daily medical practices in Turkey.
Collapse
Affiliation(s)
- H Erdem
- Department of Infectious Diseases and Clinical Microbiology, Gulhane Medical Academy, Ankara, Turkey.
| | - O Ak
- Department of Infectious Diseases and Clinical Microbiology, Dr. Lutfi Kirdar Training and Research Hospital, Istanbul, Turkey
| | - N Elaldi
- Department of Infectious Diseases and Clinical Microbiology, Cumhuriyet University School of Medicine, Sivas, Turkey
| | - T Demirdal
- Department of Infectious Diseases and Clinical Microbiology, Katip Celebi University School of Medicine, Izmir, Turkey
| | - S Hargreaves
- International Health Unit, Section of Infectious Diseases and Immunity, Imperial College London, Commonwealth Building, Hammersmith Campus, London, UK
| | - S A Nemli
- Department of Infectious Diseases and Clinical Microbiology, Katip Celebi University School of Medicine, Izmir, Turkey
| | - Y Cag
- Goztepe Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Medeniyet University, Istanbul, Turkey
| | - M Ulug
- Department of Infectious Diseases and Clinical Microbiology, Private Umit Hospital, Eskisehir, Turkey
| | - H Naz
- Department of Infectious Diseases and Clinical Microbiology, Kocaeli State Hospital, Kocaeli, Turkey
| | - O Gunal
- Department of Infectious Diseases and Clinical Microbiology, Samsun Training and Research Hospital, Samsun, Turkey
| | - F Sirmatel
- School of Medicine, Department of Infectious Diseases and Clinical Microbiology, Abant Izzet Baysal University, Bolu, Turkey
| | - O R Sipahi
- Department of Infectious Diseases and Clinical Microbiology, Ege University School of Medicine, Izmir, Turkey
| | - S N Alpat
- Department of Infectious Diseases and Clinical Microbiology, Osmangazi University School of Medicine, Eskisehir, Turkey
| | - G Ertem-Tuncer
- Department of Infectious Diseases and Clinical Microbiology, Ankara Training and Research Hospital, Ankara, Turkey
| | - H Sozen
- Department of Infectious Diseases and Clinical Microbiology, Mugla Sitki Kocman University School of Medicine, Mugla, Turkey
| | - O Evlice
- Department of Infectious Diseases and Clinical Microbiology, Dr. Lutfi Kirdar Training and Research Hospital, Istanbul, Turkey
| | - M Meric-Koc
- Department of Infectious Diseases and Clinical Microbiology, Kocaeli University School of Medicine, Izmit, Turkey
| | - A Dogru
- Goztepe Training and Research Hospital, Department of Infectious Diseases and Clinical Microbiology, Medeniyet University, Istanbul, Turkey
| | - V Koksaldi-Motor
- Tayfur Ata Sokmen School of Medicine, Department of Infectious Diseases and Clinical Microbiology, Mustafa Kemal University, Hatay, Turkey
| | - R Tekin
- Department of Infectious Diseases and Clinical Microbiology, Dicle University School of Medicine, Diyarbakir, Turkey
| | - D Ozdemir
- Department of Infectious Diseases and Clinical Microbiology, Duzce University School of Medicine, Konuralp, Duzce, Turkey
| | - D Ozturk-Engin
- Department of Infectious Diseases and Clinical Microbiology, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey
| | - U Savasci
- Department of Infectious Diseases and Clinical Microbiology, Gulhane Medical Academy, Ankara, Turkey
| | - E Karagoz
- Department of Infectious Diseases and Clinical Microbiology, Military Hospital, Van, Turkey
| | - Y Cekli
- Department of Infectious Diseases and Clinical Microbiology, Gulhane Medical Academy, Ankara, Turkey
| | - A Inan
- Department of Infectious Diseases and Clinical Microbiology, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey
| |
Collapse
|
13
|
Oksuz E, Deniz FE, Gunal O, Demir O, Barut S, Markoc F, Erkorkmaz U. Which method is the most effective for preventing postoperative infection in spinal surgery? Eur Spine J 2015; 25:1006-11. [PMID: 25893337 DOI: 10.1007/s00586-015-3941-y] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/12/2014] [Revised: 04/07/2015] [Accepted: 04/07/2015] [Indexed: 12/19/2022]
Abstract
BACKGROUND Several methods have been used to reduce the infection rate in spinal surgeries with instrumentation. PURPOSE Which method is the most effective for preventing postoperative infection? STUDY DESIGN Basic science, animal model. OBJECTIVE In the present study, the efficiency of antibiotic prophylaxis, silver-plated screws, and local rifamycin application to the surgical site was investigated in an experimental animal model. Staphylococcus aureus was used as the pathogen. METHODS Fifty 6-month-old female Wistar albino rats were used. The animals were randomly numbered and divided into five groups of ten rats each (Group 1, control group; Group 2, titanium screw and S. aureus inoculation; Group 3, titanium screw, 0.1 ml rifamycin application to the surgical area, and bacterial inoculation; Group 4, titanium screw, single preoperative dose of IM cefazolin, and bacterial inoculation; Group 5, silver-plated screw and bacterial inoculation). Titanium micro-screws were placed into the pedicles. The control group received a sterile isotonic solution, and the other four groups received bacterial suspensions containing S. aureus. The animals were killed 15 days later. RESULTS Intensive S. aureus growth was observed in all tissue and screw samples from Group 2. The results for Group 3 were similar to those for Group 1, no growth was observed in the screw cultures. Intensive growth was observed in the five screw samples in Group 4 and in the eight samples in Group 5. CONCLUSION Our study suggests that rifamycin application to the surgical area in spinal operations with instrumentation is an effective method to prevent S. aureus infections.
Collapse
Affiliation(s)
- Erol Oksuz
- Department of Neurosurgery, Gaziosmanpasa University, Tokat, Turkey. .,, Kaşıkcıbagları m. Ahmet Yesevi c., 8. Sok. No: 3, 60000, Merkez, Tokat, Turkey.
| | | | - Ozgur Gunal
- Department of Infectious Diseases and Clinical Microbiology, Gaziosmanpasa University, Tokat, Turkey
| | - Ozgur Demir
- Department of Neurosurgery, Gaziosmanpasa University, Tokat, Turkey
| | - Sener Barut
- Department of Infectious Diseases and Clinical Microbiology, Gaziosmanpasa University, Tokat, Turkey
| | - Fatma Markoc
- Department of Pathology, Gaziosmanpasa University, Tokat, Turkey
| | - Unal Erkorkmaz
- Department of Statistics, Sakarya University, Sakarya, Turkey
| |
Collapse
|
14
|
Aygen B, Yildiz O, Akhan S, Gunal O, Taheri S, Zararsiz G, Sayan M, Rustemoglu A, Altinok ES. Impact of Interleukin 28B Genotype on the Virological Responses in Chronic Hepatitis C Treatment. Gastroenterology Res 2014; 7:123-130. [PMID: 27785282 PMCID: PMC5040535 DOI: 10.14740/gr629e] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 10/30/2014] [Indexed: 12/24/2022] Open
Abstract
Background Interleukin (IL) 28B single nucleotide polymorphisms may play a role in the clearance of hepatitis C virus (HCV). We aimed to evaluate the treatment response of chronic HCV infection patients to pegile interferon (pegIFN) and ribavirin treatment with regard to IL28B rs12979860 C/T polymorphism. Methods A total of 186 patients (mean age, 55.6 ± 10 years; 65.1% female) who underwent pegIFN and ribavirin treatment for chronic HCV infection were studied. We analyzed demographics, HCV genotype, baseline alanine aminotransferase (ALT) levels, histopathological data, viral load before treatment and at 4, 12, 24, 48, and 72 weeks from the treatment start, and IL28B genotype. IL28B polymorphism was genotyped using polymerase chain reaction based restriction fragment length polymorphism (PCR-RFLP) in all the subjects. Results One hundred forty-five (86.8%) patients were infected with viral genotype 1b, and 13.2% were infected with viral genotype 4. The rates of C/C, C/T, and T/T genotypes were 22.6%, 52.7%, and 24.7% respectively. The percentage of patients with a viral load over 400,000 IU/mL was higher in the C/T group (P = 0.020). Of the patients, 44.6% provided sustained virological response (SVR) to pegIFN and ribavirin combination treatment. The frequency of T allele was 41% in patients with SVR, whereas 59% patients provided no response (P < 0.001). SVR was obtained in 66.7%, 42.9%, and 28.3% of CC, CT, and TT groups (P = 0.001). The rates of rapid virological response (RVR), early virological response (EVR), end-of-treatment response (ETR), and SVR were higher in the CC group than other groups (P = 0.216, P < 0.001, P = 0.001, P = 0.001, respectively). The relapse and null response (NR) rates were higher in TT group and partial response rate (PR) was higher in CT group. Conclusions IL28B rs12979860 C/T gene polymorphism affects the response to antiviral treatment in the patients with chronic HCV genotypes 1b and 4 infections.
Collapse
Affiliation(s)
- Bilgehan Aygen
- Department of Infectious Diseases and Clinical Microbiology, Medical School of Erciyes University, Kayseri, Turkey
| | - Orhan Yildiz
- Department of Infectious Diseases and Clinical Microbiology, Medical School of Erciyes University, Kayseri, Turkey
| | - Sila Akhan
- Kocaeli University Medical Faculty Infectious Diseases and Clinical Microbiology, Kocaeli, Turkey
| | - Ozgur Gunal
- Department of Infectious Diseases and Clinical Microbiology, Medical School of Gaziosmanpasa University, Tokat, Turkey
| | - Serpil Taheri
- Erciyes University Betul Ziya Eren Genome and Stem Cell Center, Kayseri, Turkey
| | - Gokmen Zararsiz
- Department of Biostatistics, Medical School of Erciyes University, Kayseri, Turkey
| | - Murat Sayan
- Department of Infectious Diseases and Clinical Microbiology, Medical School of Kocaeli University, Kocaeli, Turkey
| | - Aydin Rustemoglu
- Gaziosmanpasa University Medical Faculty, Department of Medical Biology, Tokat, Turkey
| | - Elif Sargin Altinok
- Department of Infectious Diseases and Clinical Microbiology, Medical School of Kocaeli University, Kocaeli, Turkey
| |
Collapse
|
15
|
Demirturk F, Ates O, Gunal O, Bozkurt N, Aysal T, Nacar MC. IL-6 gene promoter polymorphisms: genetic susceptibility to recurrent pregnancy loss. ACTA ACUST UNITED AC 2014; 115:479-82. [PMID: 25246282 DOI: 10.4149/bll_2014_092] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
Recurrent pregnancy loss (RPL) is defined as three or more pregnancy losses before 20 weeks. RPL is a multifactorial condition with several etiologic factors including genetic abnormalities of the parents, anatomical, endocrinological, hematologic and immunologic abnormalities, infections, nutritional and environmental factors. The causes of pregnancy loss in about half of the women with RPL even after extensive investigations remain unknown. We analyzed IL-6 -174 G/C, -572 G/C, -597 G/A, -1363 G/T, -2954 G/C promoter region polymorphisms in 113 RPL patients and 113 healthy subjects by using polymerase chain reaction (PCR)-based restriction fragment length polymorphism (RFLP) assay. The -174G/C genotypic and -174C allelic frequency and the -2954G/C genotypic and -2954C allelic frequency of IL-6 was higher in RPL patients than healthy controls and a significant association was found between RPL and -174G/C, -2954G/C polymorphisms (p < 0.0001, OR: 0.28, 95% CI: 0.15-0.51, p < 0.034, OR: 0.16, 95% CI: 0.01-1.12 respectively). We found remarkably similar frequencies in RPL patients compared to controls for IL-6 -572G/C,-597G/A and -1363G/T genotypes/alleles and no association was observed between RPL and these polymorphisms. Our study supported that IL-6 -174G/C and -2954G/C polymorphisms were associated with an increased risk of RPL in Turkish patients (Tab. 3, Ref. 24).
Collapse
|
16
|
Ozturk-Engin D, Erdem H, Gencer S, Kaya S, Baran AI, Batirel A, Tekin R, Celen MK, Denk A, Guler S, Ulug M, Turan H, Pekok AU, Mermut G, Kaya S, Tasbakan M, Tulek N, Cag Y, Inan A, Yalci A, Ataman-Hatipoglu C, Gonen I, Dogan-Celik A, Bozkurt F, Gulsun S, Sunnetcioglu M, Guven T, Duygu F, Parlak E, Sozen H, Tosun S, Demirdal T, Guclu E, Karabay O, Uzun N, Gunal O, Diktas H, Haykir-Solay A, Erbay A, Kader C, Aydin O, Erdem A, Elaldi N, Kadanali A, Yulugkural Z, Gorenek L, Altındis M, Bolukcu S, Agalar C, Ormeci N. Liver involvement in patients with brucellosis: results of the Marmara study. Eur J Clin Microbiol Infect Dis 2014; 33:1253-62. [PMID: 24557334 DOI: 10.1007/s10096-014-2064-4] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2013] [Accepted: 01/20/2014] [Indexed: 12/27/2022]
Abstract
Brucellosis is a zoonotic disease that primarily affects the reticuloendothelial system. But, the extent of liver damage in due course of the disease is unclear. This study included 325 brucellosis patients with significant hepatobiliary involvement identified with microbiological analyses from 30 centers between 2000 and 2013. The patients with ≥5 times of the upper limit of normal for aminotransferases, total bilirubin level ≥2 mg/dl or local liver lesions were enrolled. Clinical hepatitis was detected in 284 patients (87.3 %) and cholestasis was detected in 215 (66.1 %) patients. Fatigue (91 %), fever (86 %), sweating (83 %), arthralgia (79 %), and lack of appetite (79 %) were the major symptoms. Laboratory tests showed anemia in 169 (52 %), thrombocytopenia in 117 (36 %), leukopenia in 81 (25 %), pancytopenia in 42 (13 %), and leukocytosis in 20 (6 %) patients. The most commonly used antibiotic combinations were doxycycline plus an aminoglycoside (n = 73), doxycycline plus rifampicin (n = 71), doxycycline plus rifampicin and an aminoglycoside (n = 27). The duration of ALT normalization differed significantly in three treatment groups (p < 0.001). The use of doxycycline and an aminoglycoside in clinical hepatitis showed better results compared to doxycycline and rifampicin or rifampicin, aminoglycoside, doxycycline regimens (p < 0.05). However, the length of hospital stay did not differ significantly between these three combinations (p > 0.05). During the follow-up, treatment failure occurred in four patients (1 %) and relapse was seen in three patients (0.9 %). Mortality was not observed. Hepatobiliary involvement in brucellosis has a benign course with suitable antibiotics and the use of doxycycline and an aminoglycoside regimen seems a better strategy in select patients.
Collapse
Affiliation(s)
- D Ozturk-Engin
- Department of Infectious Diseases and Clinical Microbiology, Haydarpasa Numune Training and Research Hospital, Istanbul, Turkey
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Barut S, Yuksek J, Sezer E, Gunal O, Koseoglu D. Morbilliform drug eruption due to pegylated α-interferon can show complete regression after switching to non-pegylated interferon. J Dermatol 2011; 38:479-81. [PMID: 21352322 DOI: 10.1111/j.1346-8138.2010.01088.x] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
Pegylated or non-pegylated α-interferon are frequently used medications for the treatment of both chronic hepatitis B and chronic hepatitis C. Skin disorders, which are mainly comprised of eczematous dermatitis, are frequently seen during treatment with this drug. However, drug eruption or morbilliform eruptions due to interferons have been rarely reported so far. We herein describe a patient who developed morbilliform drug eruption under treatment with pegylated interferon. She was able to continue treatment after switching from pegylated interferon to conventional interferon.
Collapse
Affiliation(s)
- Sener Barut
- Department of Infectious Diseases and Clinical Microbiology, Gaziosmanpasa University, Faculty of Medicine, Tokat, Turkey
| | | | | | | | | |
Collapse
|
18
|
|